Antivert (Meclizine) Is Not Appropriate for Treating Tinnitus
Meclizine (Antivert) should not be used to treat tinnitus, as there is no evidence supporting its efficacy for this indication, and the American Academy of Otolaryngology–Head and Neck Surgery explicitly recommends against routine pharmacologic therapy for persistent, bothersome tinnitus. 1
Why Meclizine Is Not Indicated
No evidence-based support: The 2014 AAO-HNS clinical practice guideline specifically states that clinicians should not routinely recommend antidepressants, anticonvulsants, anxiolytics, or intratympanic medications for primary treatment of persistent, bothersome tinnitus—and antihistamines like meclizine fall into this category of unproven pharmacologic interventions. 1
Mechanism mismatch: Meclizine is an antihistamine primarily indicated for vertigo and motion sickness, not for the neurophysiologic mechanisms underlying tinnitus. 2 While various medications including antihistamines have been used off-label for tinnitus, none have FDA approval for this indication. 3
Risk without benefit: The guideline emphasizes avoiding unproven therapies that carry significant potential side effects, including drowsiness, sedation, and anticholinergic effects (particularly problematic in elderly patients), when there is insufficient evidence of efficacy. 1 Meclizine's FDA label warns about drowsiness, interaction with sedatives/alcohol, and caution in patients with glaucoma, breathing problems, or prostate enlargement. 2
What Should Be Done Instead
The evidence-based approach prioritizes cognitive-behavioral therapy (CBT) as the only treatment proven to improve quality of life in tinnitus patients, based on high-quality randomized controlled trials. 4
First-Line Interventions (in order of priority):
Education and counseling should be provided to all patients with persistent, bothersome tinnitus to explain natural history and set realistic expectations. 4
Cognitive-behavioral therapy (CBT) is the only intervention with strong evidence for improving quality of life and reducing tinnitus-related distress. 1, 4
Hearing aid evaluation is recommended for all patients with documented hearing loss (even mild or severe unilateral loss) and persistent, bothersome tinnitus. 4
Second-Line Option:
- Sound therapy (white noise, nature sounds, masking devices) may be offered, though evidence is less robust than for CBT. 4
Critical Initial Evaluation Steps
Before considering any treatment, clinicians must:
Perform targeted history and physical examination to identify potentially treatable underlying conditions (cerumen impaction, temporomandibular joint dysfunction, vascular abnormalities, ototoxic medication exposure). 1, 4
Obtain comprehensive audiologic examination within 4 weeks for patients with unilateral, persistent, or hearing-associated tinnitus. 4
Screen for psychiatric comorbidities (anxiety, depression) requiring urgent separate intervention, as suicide has been reported in tinnitus patients with coexisting psychiatric illness. 1, 4
Avoid routine imaging unless focal neurological abnormalities are present. 4
Common Pitfalls to Avoid
Do not prescribe medications as first-line therapy: Systematic reviews and RCTs show insufficient benefit with preponderance of harm over benefit for pharmacologic approaches. 1, 4
Do not recommend dietary supplements (Ginkgo biloba, melatonin, zinc): RCTs demonstrate no therapeutic benefit. 1, 4
Do not delay audiologic testing: Must be completed within 4 weeks for appropriate patients. 4
Set realistic expectations: The goal is improving quality of life and reducing distress, not eliminating the auditory perception itself. 4